CORT — Corcept Therapeutics Incorporated stock price and chart

Share this page

CORT

$114.03-1.05%

as of close, Oct 1, 2026

☾ AH $114.03 -1.05%

Corcept Therapeutics IncorporatedStock · Health CareNasdaq Composite 0.02%Russell 1000 0.01%Russell 3000 0.01%US Stock Market 0.01%

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

10.020.030.040.050.060.070.080.090.0100.0110.0120.0050.0M100.0M$114.03

2026-10-01

Price$114.03

MA20$88.61

MA50$72.27

Vol4.7M

What would $1,000 invested in CORT be worth today? →

CORT returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $114.03
Change YTD: +227.66%
Next earnings: Nov 3, 2026
Market cap: 12.3B2016-12 806.1M2026-10 12.3B+1429.7% over the window
Enterprise value: 12B
Shares outstanding: 108.1M2016-06 110.6M2026-06 108.1M-2.3% over the window
52W low: $28.66
52W high: $126.38
From 52W high: -9.78%
From 52W low: +297.85%
52W range: 87%
Beta: 0.45

Volume

Rel volume: 0.58×
30D volume: 1.5M
30D $ vol: 164.6M

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1M0 insider-days of buying (no priced lot) and 3 of selling ($2.3M) in the last 30 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$2.3M
Insider net 3M0 insider-days of buying (no priced lot) and 20 of selling ($54.0M) in the last 91 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$54.0M
Insider net 1Y1 insider-day of buying ($3.3M) and 38 of selling ($81.5M) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$78.2M

Form 4 transactions by trade date, as filed; latest on file 2026-09-16.

Fundamentals

Sales (ttm): 830.8M2016-12 81.3M2026-06 830.8M+921.6% over the window
Sales/share: $7.692016-12 $0.722026-06 $7.69+967.4% over the window
EPS (ttm): $0.482016-06 $0.012026-06 $0.48+3915.4% over the window
FCF (ttm): 106.9M2016-06 9.9M2026-06 106.9M+977.7% over the window
FCF/share: $0.992016-06 $0.092026-06 $0.99+1002.6% over the window
Book value/share: $6.532016-06 $0.232026-06 $6.53+2714.0% over the window
Net margin: 6.64%2016-12 10.0%2026-06 6.6%-33.6% over the window
ROE: 7.82%2016-06 5.1%2026-06 7.8%+52.5% over the window
ROA: 6.21%2016-06 2.3%2026-06 6.2%+168.2% over the window
Current ratio: 2.862016-06 2.002026-06 2.86+43.2% over the window

Growth (CAGR, ttm) · 10Y

Sales: +16.03%2025-06-30 → 2026-06-30716.1M → 830.8M (+16.0% total)+24.72%2023-06-30 → 2026-06-30428.2M → 830.8M (+94.0% total)+19.35%2021-06-30 → 2026-06-30343.1M → 830.8M (+142.2% total)+27.73%2016-12-31 → 2026-06-3081.3M → 830.8M (+921.6% total)
Net income: -58.74%2025-06-30 → 2026-06-30133.7M → 55.2M (-58.7% total)-16.45%2023-06-30 → 2026-06-3094.6M → 55.2M (-41.7% total)-10.78%2021-06-30 → 2026-06-3097.6M → 55.2M (-43.5% total)+45.30%2016-06-30 → 2026-06-301.3M → 55.2M (+4093.2% total)
FCF: -40.79%2025-06-30 → 2026-06-30180.5M → 106.9M (-40.8% total)-7.43%2023-06-30 → 2026-06-30134.8M → 106.9M (-20.7% total)-4.40%2021-06-30 → 2026-06-30133.9M → 106.9M (-20.1% total)+26.84%2016-06-30 → 2026-06-309.9M → 106.9M (+977.7% total)
Shares: +2.59%2025-06-30 → 2026-06-30105.4M → 108.1M (+2.6% total)+1.77%2023-06-30 → 2026-06-30102.5M → 108.1M (+5.4% total)-1.39%2021-06-30 → 2026-06-30115.9M → 108.1M (-6.8% total)-0.23%2016-06-30 → 2026-06-30110.6M → 108.1M (-2.3% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: -57.76%2025-06-30 → 2026-06-30$1.13 → $0.48 (-57.7% total)-16.70%2023-06-30 → 2026-06-30$0.83 → $0.48 (-42.2% total)-8.88%2021-06-30 → 2026-06-30$0.76 → $0.48 (-37.2% total)+44.68%2016-06-30 → 2026-06-30$0.01 → $0.48 (+3915.4% total)
Sales/share: +13.11%2025-06-30 → 2026-06-30$6.80 → $7.69 (+13.1% total)+22.55%2023-06-30 → 2026-06-30$4.18 → $7.69 (+84.1% total)+21.03%2021-06-30 → 2026-06-30$2.96 → $7.69 (+159.7% total)+28.32%2016-12-31 → 2026-06-30$0.72 → $7.69 (+967.4% total)
FCF/share: -42.28%2025-06-30 → 2026-06-30$1.71 → $0.99 (-42.3% total)-9.04%2023-06-30 → 2026-06-30$1.31 → $0.99 (-24.8% total)-3.05%2021-06-30 → 2026-06-30$1.15 → $0.99 (-14.4% total)+27.13%2016-06-30 → 2026-06-30$0.09 → $0.99 (+1002.6% total)
Book value/share: +8.21%2025-06-30 → 2026-06-30$6.03 → $6.53 (+8.2% total)+16.66%2023-06-30 → 2026-06-30$4.11 → $6.53 (+58.8% total)+7.69%2021-06-30 → 2026-06-30$4.51 → $6.53 (+44.8% total)+39.62%2016-06-30 → 2026-06-30$0.23 → $6.53 (+2714.0% total)
Price: +35.37%2025-10-01 → 2026-10-01$84.25 → $114.03 (+35.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+63.14%2023-10-02 → 2026-10-01$26.29 → $114.03 (+333.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+41.88%2021-10-01 → 2026-10-01$19.84 → $114.03 (+474.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+33.17%2016-09-30 → 2026-10-01$6.50 → $114.03 (+1654.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +35.37%2025-10-01 → 2026-10-01$84.25 → $114.03 (+35.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+63.14%2023-10-02 → 2026-10-01$26.29 → $114.03 (+333.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+41.88%2021-10-01 → 2026-10-01$19.84 → $114.03 (+474.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+33.17%2016-09-30 → 2026-10-01$6.50 → $114.03 (+1654.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 238.8×2016-12 179.052026-10 223.46+24.8% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 1925.2×2016-12 118.142026-10 1925.18+1529.5% over the window
Fwd P/E: 26.4×
P/S (ttm)Market cap ÷ TTM revenue.: 14.8×2016-12 27796.232026-10 14.84-99.9% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 17.5×2016-12 25.802026-10 17.47-32.3% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 115.3×2016-12 45.082026-10 115.33+155.8% over the window
EV/EBITDA (fy): 1487.8×
EV/Sales (ttm): 14.5×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 0.87%2016-09 2.2%2026-06 1.1%-48.7% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 108.1M ÷ 105.4M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -2.59%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-2.59%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($7.7B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -2.59%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($42.5M) ÷ today's market cap ($12.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.34%2016-09 0.0%2026-06 0.5%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $42.5M + TTM dividends $0) ÷ today's market cap ($12.3B). Same caveat as the cash buyback yield.: 0.34%2016-09 0.0%2026-06 0.5%

Vs own 10Y history

P/E: 99th
P/OI: 99th
P/S: 89th
P/B: 87th
P/FCF: 99th

Bar = where today’s multiple sits in CORT’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-01

-1.05%

-3.78%

+0.57%

+28.87%

YTD

+227.66%

+35.34%

+474.72%

Recent filings

Sep 238-K · Directors or officers; compensation; Regulation FD disclosure
Sep 16Insider sale · Vieira Roberto Wandenkolk (President, Oncology) sold 296 shares for $30K at $100.82 under a 10b5-1 plan
Sep 15Insider sale · WILSON JAMES N (Director) sold 10,000 shares for $1.1M at $110.27–$111.70 under a 10b5-1 plan
Sep 14Insider sale · Lyon Joseph Douglas (See Remarks) sold 10,000 shares for $1.1M at $113.32–$114.12 under a 10b5-1 plan
Sep 2Insider sale · Vieira Roberto Wandenkolk (President, Oncology) sold 58,333 shares for $6.5M at $109.35–$115.44 under a 10b5-1 plan

All filings and insider trades →

Financial statements

Open full CORT financials →

Loading financial statements…

Ticker	Name	1M	1D
NVS	Novartis AG	-12.53%	-1.07%
NVO	Novo Nordisk A/S	-17.11%	-1.35%
SNY	Sanofi ADS	-8.34%	-1.36%
GSK	GSK plc American Depositary Shares (Each representing two Ordinary Shares)	-6.87%	-2.06%
NTRA	Natera Inc.	+27.34%	-1.17%
ARGX	argenx SE American Depositary Shares	-8.99%	-2.39%
TAK	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	-2.03%	-1.81%
TEVA	Teva Pharmaceutical Industries Limited American Depositary Shares	+8.62%	-0.73%

CORT — Corcept Therapeutics Incorporated price, chart and key statistics